CCR2 Expression Profiling for Antagonist Response Stratification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pharmacological interventions face challenges in effectively stratifying patient populations based on their responsiveness to C-C chemokine receptor type 2 (CCR2) antagonists due to diverse genetic and genomic profiles.

Innovation Solution

A method for treating diseases by measuring the CCR2 profile of patients, selecting compounds based on this profile, and administering CCR2 antagonists, agonists, or mixed agonist-antagonists to enhance treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If pharmacological interventions are applied to diverse patient populations, then treatment coverage is improved, but treatment efficacy decreases due to varied genetic and genomic profiles

Engineering Contradiction:

Improvetreatment coverageVSAvoidtreatment efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments the patient population into distinct subgroups based on CCR2 genetic and genomic profiles. By dividing the heterogeneous population into homogeneous subgroups with similar CCR2 characteristics, the patent enables tailored pharmacological interventions that improve treatment efficacy within each subgroup while maintaining broad adaptability across the entire population through multiple stratification categories.

Inventive Principle:

Principle #1Segmentation

2Adaptability or versatility

If patient populations are stratified using traditional methods, then treatment personalization is improved, but measurement precision is insufficient due to lack of specific biomarker profiles

Engineering Contradiction:

Improvetreatment personalizationVSAvoidbiomarker profile accuracy

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent introduces CCR2 genetic and genomic profiles as intermediary biomarkers that mediate between traditional clinical characteristics and treatment response. These CCR2-specific biomarkers serve as precise measurement tools that enable accurate patient stratification and prediction of pharmacological intervention outcomes, thereby improving both measurement precision and treatment personalization.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If comprehensive patient profiling is performed to improve treatment selection, then treatment efficacy is improved, but device complexity and analysis requirements increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidprofiling system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and focuses specifically on CCR2-related genetic and genomic characteristics from the comprehensive set of all possible patient biomarkers. By isolating and analyzing only the CCR2-specific profiles that are most relevant to pharmacological intervention response, the patent reduces the complexity of the profiling system while maintaining high treatment efficacy through targeted, rather than exhaustive, analysis.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20250290127A1Method And Kit For CCR2 Expression Profiling And Disease Stratification

Publication Date: 2025.09.18 PLUMERIA THERAPEUTICS INC

AI summary

Methods of treating disease include measuring a CCR2 profile of a patent, selecting a CCR2 antagonist based on the CCR2 profile of the patient, and administering the CCR2 antagonist to the patient. Methods for stratifying one or more patients for pain medication based on a CCR2 profile include measuring a CCR2 profile of one or more patients and partitioning the one or more patients into predetermined groups or subgroups based on the CCR2 profile of the one or more patients. Kits for performing the methods are also described.